The geko® device’s Post

Complete chronic wound healing as a primary endpoint necessitates trials with large sample sizes and prolonged follow-up to achieve adequate statistical power. Listen to our Head of Clinical Studies, Kieron Day Ph.D., present a novel study metric - Percentage Area Reduction (PAR) - measured over a 4-week period, as a surrogate end point, and how the addition of the geko device significantly increased the PAR rate compared to compression therapy alone in the same cohort in our recently published study. https://lnkd.in/evDXtmyU

Complete chronic wound healing as a primary endpoint necessitates trials with large sample sizes and prolonged follow-up to achieve adequate statistical power. Listen to our Head of Clinical Studies, Kieron Day Ph.D., present a novel study metric - Percentage Area Reduction (PAR) - measured over a 4-week period, as a surrogate end point, and how the addition of the geko device significantly increased the PAR rate compared to compression therapy alone in the same cohort in our recently published study. https://lnkd.in/evDXtmyU

Long-term use of finerenone is anticipated to increase the duration of event-free survival by as much as 3 years for individuals with heart failure and mildly reduced or preserved ejection fraction. Vaduganathan M, Claggett BL, Desai AS, et al. Estimated Long-Term Benefits of Finerenone in Heart Failure: A Prespecified Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. Published online September 27, 2024. doi:10.1001/jamacardio.2024.3782

Extensive heterogeneity in the expression of steroid receptors in superficial peritoneal endometriotic lesions - Selected by our Chief Editors, Nick Macklon and Juan A. García Velasco, as one of two Editor’s Choice papers in the February Issue of RBMO. The results from this study illustrate the considerable variability in immunostaining patterns of steroid receptors and proliferation markers among superficial peritoneal lesions, even within individual patients. The authors, Jane Girling, Dr Eliza Colgrave, Janet Keast, Cameron Nowell, Martin Healey, Peter Rogers, and Sarah Holdsworth-Carson, demonstrate the diversity in the expression of steroid hormone receptors and Bcl-2 between lesions, even within an individual patient, and discuss how this diversity makes it difficult to find commonalities that would allow patient stratification in a clinical setting. Read the paper in full from issue 48.2 now https://lnkd.in/eHfCcX82 #FemaleReproductiveHealthAndFertility #Endometriosis #EndometrioticLesion #SteroidReceptor #Proliferation #Apoptosis

New Journal Club Article featuring Tiffany Moon, MD, FASA! 📚 Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Patients With Severe Renal Impairment: A Randomized, Double-Blinded Study "In patients with severe renal impairment, neuromuscular blockade with rocuronium followed by reversal with sugammadex provides a significantly faster return of neuromuscular function compared to cisatracurium and neostigmine, without any major adverse effects." "The mean time to recovery of TOFR ≥90% was significantly faster with sugammadex at 3.5 (±1.6) min compared with neostigmine at 14.8 (±6.1) min." Read full article here: https://lnkd.in/gb6Tib4v #PatientSafety #Sugammadex #Neostigmine #TwitchView

🌟Exciting News in Osteoarthritis Research! 🌟 We are proud to be one of the clinical trial sites for LEVICEPT LTD's groundbreaking study on the neurotrophin-3 (NT-3) inhibitor, LEVI-04, designed to relieve patients suffering from moderate-to-severe knee osteoarthritis. 💊 🦵🏻 Newly released results from the phase 2 trial have shown promising outcomes, with patients experiencing a significant reduction in pain. Importantly, LEVI-04 offers relief with a good safety profile. Knee osteoarthritis is a debilitating disease limiting mobility and deteriorating the quality of life of the aging population. However, effective medical treatment to retard or cure the disease is still lacking. We are excited to see a breakthrough with the positive results readout. 😃 Thank you to our dedicated team and all participants who made this research possible! 🙏🏻 Learn more about this study 👉 https://lnkd.in/eeYYRrMV #Osteoarthritis #ClinicalTrials #Levicept #HealthcareInnovation #Medicine #Research #LEVI04 #hkccr

💡 Join Dr. Vince Clinical Research for an upcoming webinar on managing renal and hepatic impairment trials. These trials are essential for assessing the impact of organ impairment on #pharmacokinetics (PK), but recruitment challenges make them more complex than standard clinical studies. Learn how tools like population PK (#PopPK) and physiologically based PK (#PBPK) modeling, combined with adaptive trial designs, can reduce patient burden and improve trial outcomes. ➡️ Learn more + register here: https://buff.ly/4gASg2T 🌟 Featured speakers: Korey Nevitt Harry Alcorn PharmD George Atiee Toni Grant #ADME #DrugDevelopment #ClinicalResearch #PatientRecruitment #NASH #NAFLD #TherapeuticAreas #TranslationalResearch #NonalcoholicSteatohepatitis

Open access….. free article Duration of botulinum toxin efficacy in cervical dystonia clinical trials: A scoping review Highlights • Botulinum toxin (BoNT) is first-line treatment for cervical dystonia (CD). • BoNT effect duration can impact quality of life if effect wanes prior to next dose. • Duration definitions in trials vary and are not always suitable for clinical practice. • Clinicians should aim to keep patients with CD as symptom-free as possible. • Reinjection intervals should be flexible, based on the individual patient's needs. Log in : https://lnkd.in/gGDdvZuD IAPRD Secretariat

Our outstanding team published a valuable research output entitled: The impact of synbiotic on serum sCD163/sTWEAK, paraoxonase 1, and lipoproteins in patients with chronic heart failure: a randomized, triple-blind, controlled trial, August, 2024. Standard Mean Difference (SMD) is one of the most important “Effect sizes” to show the grade of treatment efficacy in RCTs. In addition, Intention-to-treat (ITT) analysis was performed in this RCT for sensitivity analysis.  DOI: 10.1038/s41598-024-69560-8 #randomizedcontrolledtrials #RCT #intentiontotreat #ITT #effectsize #sensitivityanalysis #chronicheartfailure #probiotic #synbiotic

Featuring research by a team of nephrologists and BC Renal employees, a recent publication in the Clinical Kidney Journal investigates the utility of the Kidney Failure Risk Equation (KFRE) in patients undergoing hemodialysis. The KFRE, which projects the risk of kidney failure progression using metrics such as a patient's urine and glomerular filtration rate, has been validated in over 30 countries and can facilitate better vascular access planning. Building off this preliminary knowledge, our study of over 2500 kidney patients finds "KFRE... has the potential to improve [vascular access] resource utilization" by more accurately projecting when patients may require dialysis ahead of time. Read the article here: https://lnkd.in/gu-eQgGx